What is your current preferred approach in the management of metasatic sarcomatoid NSCLC?  

Specifically, would carbo-taxol-bev-atezo (IMpower 150) be an attractive option given the activity of bev-atezo in sarcomatoid PDL1+ metastatic RCC (IMmotion 151)?



Answer from: Medical Oncologist at Academic Institution